Reduction of Intravenous Antihypertensives through Clinical Decision Support in a Large Safety Net System
Asymptomatic severe hypertension (also known as hypertensive urgency) is frequently encountered in the hospital. Previous evidence suggests that management with one-time doses of intravenous (IV) antihypertensives may increase adverse events. Despite this, single-dose treatment remains common in the...
Saved in:
Published in | Joint Commission journal on quality and patient safety Vol. 49; no. 6-7; p. 291 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
01.06.2023
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Asymptomatic severe hypertension (also known as hypertensive urgency) is frequently encountered in the hospital. Previous evidence suggests that management with one-time doses of intravenous (IV) antihypertensives may increase adverse events. Despite this, single-dose treatment remains common in the emergency department and inpatient settings.
This quality initiative was launched at New York City Health + Hospitals, the largest safety net hospital system in the United States. The initiative involved two changes to electronic orders for IV hydralazine and IV labetalol: a nonintrusive advisory statement within the order instructions and a mandatory requirement to document the indication for IV antihypertensive use.
This initiative took place from November 2021 to October 2022. Of the indications selected for IV antihypertensive orders, 60.7% were for hypertensive emergency, 15.3% were for patients who were strictly NPO, 21.2% were for other, and 2.8% selected more than one indication. For ED-only encounters, aggregate IV hydralazine and IV labetalol orders per 1,000 patient encounters were 2.53 preintervention and 1.55 postintervention (38.7% reduction, p < 0.001). For inpatient encounters, aggregate IV hydralazine and IV labetalol orders per 1,000 patient-days were 18.25 preintervention and 15.81 postintervention (13.4% reduction, p < 0.001). Similar trends were observed for individual orders of IV hydralazine and IV labetalol. There were significant reductions in 7 of the 11 hospitals in inpatient administration of aggregate IV hydralazine and labetalol orders per 1,000 patient-days.
This quality improvement initiative successfully reduced unnecessary IV antihypertensive use in an 11-hospital safety net system. |
---|---|
AbstractList | Asymptomatic severe hypertension (also known as hypertensive urgency) is frequently encountered in the hospital. Previous evidence suggests that management with one-time doses of intravenous (IV) antihypertensives may increase adverse events. Despite this, single-dose treatment remains common in the emergency department and inpatient settings.
This quality initiative was launched at New York City Health + Hospitals, the largest safety net hospital system in the United States. The initiative involved two changes to electronic orders for IV hydralazine and IV labetalol: a nonintrusive advisory statement within the order instructions and a mandatory requirement to document the indication for IV antihypertensive use.
This initiative took place from November 2021 to October 2022. Of the indications selected for IV antihypertensive orders, 60.7% were for hypertensive emergency, 15.3% were for patients who were strictly NPO, 21.2% were for other, and 2.8% selected more than one indication. For ED-only encounters, aggregate IV hydralazine and IV labetalol orders per 1,000 patient encounters were 2.53 preintervention and 1.55 postintervention (38.7% reduction, p < 0.001). For inpatient encounters, aggregate IV hydralazine and IV labetalol orders per 1,000 patient-days were 18.25 preintervention and 15.81 postintervention (13.4% reduction, p < 0.001). Similar trends were observed for individual orders of IV hydralazine and IV labetalol. There were significant reductions in 7 of the 11 hospitals in inpatient administration of aggregate IV hydralazine and labetalol orders per 1,000 patient-days.
This quality improvement initiative successfully reduced unnecessary IV antihypertensive use in an 11-hospital safety net system. |
Author | Alaiev, Daniel Tsega, Surafel Manchego, Peter Alarcon Shin, Dawi Krouss, Mona Chandra, Komal Garcia, Mariely Zaurova, Milana Talledo, Joseph Cho, Hyung J |
Author_xml | – sequence: 1 givenname: Mona surname: Krouss fullname: Krouss, Mona – sequence: 2 givenname: Surafel surname: Tsega fullname: Tsega, Surafel – sequence: 3 givenname: Daniel surname: Alaiev fullname: Alaiev, Daniel – sequence: 4 givenname: Joseph surname: Talledo fullname: Talledo, Joseph – sequence: 5 givenname: Komal surname: Chandra fullname: Chandra, Komal – sequence: 6 givenname: Peter Alarcon surname: Manchego fullname: Manchego, Peter Alarcon – sequence: 7 givenname: Milana surname: Zaurova fullname: Zaurova, Milana – sequence: 8 givenname: Dawi surname: Shin fullname: Shin, Dawi – sequence: 9 givenname: Mariely surname: Garcia fullname: Garcia, Mariely – sequence: 10 givenname: Hyung J surname: Cho fullname: Cho, Hyung J |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37024423$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9tKAzEYhIMo9qAv4IXkBXZN8qd7uCz1VCgKroJ3JUn_bbO02TXJFvbtrajDwFx9w8yEnLvWISE3nKWc8eyuSRvTfKWCCUjZyYyfkTEvoUg48M8RmYTQMAZZVhaXZAQ5E1IKGBP7hpveRNs62tZ06aJXR3RtH-jcRbsbOvQRXbBHDDTufNtvd3Sxt84ataf3aGz4Qau-61ofqXVU0ZXyW6SVqjEO9AUjrYYQ8XBFLmq1D3j9l1Py8fjwvnhOVq9Py8V8lRhgeUzKIivZTOoaylwrOQN5EqvZbMNqk2kNiHhaD1jmMtNGShDaFBqhyBUvuBFTcvvb2_X6gJt15-1B-WH9_1l8A0-FW08 |
ContentType | Journal Article |
Copyright | Copyright © 2023 The Joint Commission. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: Copyright © 2023 The Joint Commission. Published by Elsevier Inc. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/j.jcjq.2023.03.001 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
EISSN | 1938-131X |
ExternalDocumentID | 37024423 |
Genre | Journal Article |
GroupedDBID | ..I .1- .FO 0R~ 186 1P~ 29J 4.4 5RE AABSN AAEDW AALRI AAQQT AAWTL AAXUO ACGFS ADBBV AFJKZ AFRHN AFTJW AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS CGR COPKO CUY CVF EBS ECM EIF EJD FDB J5H L7B NPM O9- ROL SJN SSZ XOL YJK YYQ Z5R ZUP ZXP |
ID | FETCH-LOGICAL-c307t-9869054bf397ba45344440f05d0fc6bb3eee7023e9746bc4432bc8be387a181c2 |
IngestDate | Tue Oct 15 08:55:36 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6-7 |
Language | English |
License | Copyright © 2023 The Joint Commission. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c307t-9869054bf397ba45344440f05d0fc6bb3eee7023e9746bc4432bc8be387a181c2 |
PMID | 37024423 |
ParticipantIDs | pubmed_primary_37024423 |
PublicationCentury | 2000 |
PublicationDate | 2023 Jun-Jul |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: 2023 Jun-Jul |
PublicationDecade | 2020 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | Joint Commission journal on quality and patient safety |
PublicationTitleAlternate | Jt Comm J Qual Patient Saf |
PublicationYear | 2023 |
References | 37076351 - Jt Comm J Qual Patient Saf. 2023 Jun-Jul;49(6-7):289-290 |
References_xml | |
SSID | ssj0036698 |
Score | 2.4329102 |
Snippet | Asymptomatic severe hypertension (also known as hypertensive urgency) is frequently encountered in the hospital. Previous evidence suggests that management... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 291 |
SubjectTerms | Antihypertensive Agents - adverse effects Blood Pressure Decision Support Systems, Clinical Humans Hydralazine - adverse effects Hypertension - drug therapy Labetalol - adverse effects |
Title | Reduction of Intravenous Antihypertensives through Clinical Decision Support in a Large Safety Net System |
URI | https://www.ncbi.nlm.nih.gov/pubmed/37024423 |
Volume | 49 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fT9swELYKkyZeENN-Mjb5gbcqVVY7cfNYwSY2bX2AIvGGbOeipepSoIEH_in-xZ1zjhsKmzb6EFWx5aa-r-e76913jO0naZ7kQiB4DahIZhoibSCO1BCUxfMdTJNV-WOSHp3Kb2fJWa9318lauq7NwN4-WlfyFKniPZSrq5L9D8mGRfEGvkf54hUljNd_kvGx411tTb6vLkx7Q5Sr46ouf6KHeeXz05ehH89BWwl56Jvr9F1fT7TBXeBD97-7xPD-iS5cJucEas9oft-ELava6RFESLNAIJ-ofIkmUTp5xtb-slksKHZ8DOrTjtokHAnTJVCA9-T6CqeHrI_xXJe4KaEUfhVnmM8hX3T-wugEL4ZilWQ1AFK4GSrcT6JpmxM0MpGYeuSlkeoqWOrt9UDxUwxiNpjZ2eXAfRJR196bjMK7-NVAQSg0TSQVOv99dI2Mux3aYBtq5BTqxAWH6OAXaZqNfF0WpRCuP8wWe94usObFNNbMdIdtezeEjwlTL1gPqpesDHjii4J38MQf4Il7PPEWT7zFE_d44mXFNW_wxAlPHPHECU-v2OmXz9ODo8i34ogsHgJ1lLnGZYk0BZqvRstESHzFRZzkcWFTYwQA4DcTgO5paqyUYmjsyIAYKY02pB2-ZpvVooK3jCv0UDPIYpNnOS6ocB5YY2MthTGpyd6xN7Qz5xfEt3Le7tnuH0fes60VuvbYswJ_4PABrcXafGxk9BuDi3AK |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+of+Intravenous+Antihypertensives+through+Clinical+Decision+Support+in+a+Large+Safety+Net+System&rft.jtitle=Joint+Commission+journal+on+quality+and+patient+safety&rft.au=Krouss%2C+Mona&rft.au=Tsega%2C+Surafel&rft.au=Alaiev%2C+Daniel&rft.au=Talledo%2C+Joseph&rft.date=2023-06-01&rft.eissn=1938-131X&rft.volume=49&rft.issue=6-7&rft.spage=291&rft_id=info:doi/10.1016%2Fj.jcjq.2023.03.001&rft_id=info%3Apmid%2F37024423&rft_id=info%3Apmid%2F37024423&rft.externalDocID=37024423 |